山东东方海洋科技股份有限公司 关于公司无控股股东、实际控制人的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002086 证券简称：*ST 东洋 公告编号：2023-092 山东东方海洋科技股份有限公司（以下简称"公司"）已召开 2023 年第一次临时 股东大会，对公司第七届董事会进行了换届选举。换届选举后，公司根据《中华人 民共和国公司法》(以下简称《公司法》)及《上市公司收购管理办法》(以下简称《收 购管理办法》)等法律法规的相关规定，结合公司股权结构和董事会成员提名情况， 以及公司股东大会的表决情况，对公司控制权情况进行了谨慎甄别。经公司审慎判 断认定本次换届选举后，公司无控股股东、实际控制人。具体情况公告如下： 一、关于公司控股股东、实际控制人认定的法律依据 1．《公司法》的规定 《公司法》第二百一十六条规定，控股股东，是指其出资额占有限责任公司资 本总额百分之五十以上或者其持有的股份占股份有限公司股本总额百分之五十以上 的股东；出资额或者持有股份的比例虽然不足百分之五十，但依其出资额或者持有 的股份所享有的表决权已足以对股东会 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2023-091 山东东方海洋科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决提案的情形。 2．本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间： （1）现场会议的召开时间为：2023 年 8 月 18 日（星期五）上午 9:30。 （2）网络投票时间：2023 年 8 月 18 日，其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2023 年 8 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网系统进行网络投票的具体时间为 2023 年 8 月 18 日 9:15-15:00 的任意时间。 2．现场会议地点：山东省烟台市莱山区澳柯玛大街18号公司会议室。 3．会议召开方式： 本次股东大会采用现场表决与网络投票相结合的方式召开。 4．会议届次：2023年第一次临时股东大会。 5． ...

湖南启元律师事务所 关于 山东东方海洋科技股份有限公司 股东湖南优禾神州股权投资合伙企业（有限合伙） 公开征集表决权相关事项的 法律意见书 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410007 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 致：湖南优禾神州股权投资合伙企业（有限合伙） 湖南启元律师事务所（以下简称"本所"）接受山东东方海洋科技股份有限 公司（以下简称"东方海洋"或"公司"）股东湖南优禾神州股权投资合伙企业 （有限合伙）（以下简称"湖南优禾"）的委托，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东大会规则》《公开征集上市公司股东权利管理暂行规 定》（以下简称"《暂行规定》"）等现行法律、法规和规范性文件的有关规定 以及《山东东方海洋科技股份有限公司章程》，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，就湖南优禾向截至 2023 年 8 月 10 日下午股市交易结 束后在中国证券登记结算有限责任公司深圳分公司登记在册全体股 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2023-089 山东东方海洋科技股份有限公司 关于股东公开征集表决权的公告 股东湖南优禾神州股权投资合伙企业（有限合伙）保证信息披露的内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别声明： 选举 1.07 龚俊宇女士为公司第八届董事会非独立董事； 选举 2.03 伍喆先生为公司第八届董事会独立董事； 选举 3.03 刘泽清女士为公司第八届监事会股东代表监事； 山东东方海洋科技股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日 收到股东湖南优禾关于公开征集表决权的函，根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司治理准则》等法律法规及《山东东方海洋科技 股份有限公司章程》有关规定，湖南优禾持有公司 13.22%股份，作为征集人就 公司拟于 2023 年 8 月 18 日召开的 2023 年第一次临时股东大会有关议案向公司 全体股东征集表决权。具体内容详见后附《关于公开征集表决权的函》和《征集 表决权授权委托书》。 特此公告。 山东东方 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2023-088 山东东方海洋科技股份有限公司 关于股东公开征集表决权的公告 股东朱春生先生保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别声明： 1．本次征集表决权为依法公开征集，征集人朱春生符合《证券法》第九十 条、《上市公司股东大会规则》第三十一条、《公开征集上市公司股东权利管理 暂行规定》第三条规定的征集条件； 山东东方海洋科技股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日 收到股东朱春生关于公开征集表决权的函及报告书，为保证（预）重整相关工作 连续性、稳定性，顺利推进公司重整，维护公司和股东利益，朱春生作为持有公 司 1%以上有表决权股份的股东，现决定就公司拟于 2023 年 8 月 18 日（星期五） 9:30 召开的 2023 年第一次临时股东大会审议的选举非独立董事、独立董事、监 事会股东代表监事、与相关方签订《债务重组与化解协议》暨关联交易的议案向 公司全体股东征集表决权。具体内容详见后附《关于公开征集表决权的函》《 ...

山东东方海洋科技股份有限公司 关于股东提请增加股东大会临时提案的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002086 证券简称：*ST 东洋 公告编号：2023-087 因此，湖南优禾提请公司董事会按照相关规定在收到临时提案后及时将上述 议案予以采纳，并将其提交公司 2023 年第一次临时股东大会审议。 经公司董事会核查：截至本公告披露日，湖南优禾持有公司股份 100,000,000 股，占公司总股本的比例 13.22%，其提案内容未超出法律法规和《公司章程》的 规定及股东大会职权范围，但公司收到提案时间为 2023 年 8 月 8 日，湖南优禾未 向公司董事会提供持有公司 3%以上股份的证明文件、提案人关于提案符合《上市 公司股东大会规则》及深交所相关规定的声明，因此，提案时间和程序不符合 《公司章程》《股东大会议事规则》《深圳证券交易所股票上市规则（2023 年修 订）》的有关规定。 根据《国有企业、上市公司选聘会计师事务所管理办法》第五条："上市公司 聘用或解聘会计师事务所，应当由审计委员会审议同意后，提交董事会审议，并 由股东大会决 ...

山东鑫同律师事务所 关于山东东方海洋科技股份有限公司 股东临时提案不予提交股东大会审议之 法律意见书 地址:山东省烟台市芝罘区万达金融中心B座11楼 电话:0535-6213036 邮编: 264000 BB 田 本所律师就出具本法律意见书声明如下: 1. 本所律师仅根据本法律意见书出具日以前已经发生或存在的 事实和我国现行有效的法律、法规和其他规范性文件发表法律意见。 2. 本所律师就出具本法律意见书无法获得独立证明、证据的事实, 依赖当事人的陈述及当事人提供的文件。 3. 本所律师就出具本法律意见书进行的档案、数据查询,因相关 部门档案、网站数据库在更新上可能存在着延后,故本所律师仅根据 调查之日部门档案、网站数据库已有且可以查阅之记载发表意见。 4. 为出具本法律意见书,本所律师对公司提供的文件资料进行了 审查,并就上述文件资料中涉及的有关事实向公司高级管理人员进行 了核实,公司已向本所做出保证和承诺,保证公司向本所提供的资料 文件和对有关事实的口头及书面说明均为真实、准确、完整,无重大 遗漏。 5. 本法律意见书仅供山东东方海洋科技股份有限公司股东临时 提案不予提交股东大会审议事宜之用。本所律师同意将 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2023-086 山东东方海洋科技股份有限公司 关于持股5%以上股东一致行动人终止增持股份的公告 湖南优禾保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 增持计划基本情况：山东东方海洋科技股份有限公司（以下简称"公司"）持 股5%以上股东湖南优禾神州股权投资合伙企业（有限合伙）（以下简称"湖南优 禾"）一致行动人湖南神州行者资本管理有限公司（以下简称"神州行者资本"或 "增持人"）计划自2023年4月10日起六个月内（法律法规及深圳证券交易所业务 规则等有关规定不准增持的期间除外）通过深圳证券交易所交易系统允许的方式 （包括但不限于集中竞价、大宗交易等）增持公司股份，本次拟增持股份的金额 不低于人民币1.1亿元，不超过人民币2.2亿元，平均价格不高于2元/股。 增持计划实施情况：截至本公告披露日，神州行者资本未增持公司股份，未 能完成本次增持计划。 公司于2023年4月4日在指定媒体披露了《关于持股5%以上股东一致行动人增 持股份计划的 ...

Financial Condition and Performance - The company reported a severe deterioration in financial condition, leading to insolvency, with management and operational controls failing to comply effectively, resulting in uncertain financial data [6]. - The annual audit firm issued an audit report with a disclaimer of opinion for the fiscal year 2022, indicating insufficient evidence to form an opinion on the financial statements [8]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [11]. - The company's operating revenue for 2022 was ¥629,302,311.08, representing a 61.79% increase compared to ¥388,969,421.15 in 2021 [30]. - The net profit attributable to shareholders of the listed company was -¥1,584,905,386.54, a decrease of 57.96% from -¥1,003,357,160.46 in the previous year [30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥898,841,849.70, which is an 11.04% increase in loss compared to -¥809,463,845.89 in 2021 [30]. - The cash flow from operating activities was -¥42,962,176.47, a significant decline of 246.09% from ¥29,408,960.11 in 2021 [30]. - The total assets at the end of 2022 were ¥2,001,961,772.53, down 24.56% from ¥2,653,744,389.81 at the end of 2021 [30]. - The net assets attributable to shareholders of the listed company were -¥1,167,981,506.01, a decrease of 384.54% from ¥410,480,873.58 in 2021 [30]. - The basic and diluted earnings per share were both -¥2.10, a decrease of 57.89% from -¥1.33 in 2021 [30]. - The company reported a total profit for the year of CNY -1,572,667,695.08, a decrease of 56.84% year-on-year [61]. - The company reported a significant decline in operational performance, with management indicating serious issues in financial and internal control systems [185]. Business Operations and Strategy - The company has not changed its main business since its listing, and there have been no changes in controlling shareholders [29]. - The company operates in a region with a first-class aquaculture water quality standard, but risks such as environmental pollution and natural disasters remain [10]. - The company is positioned in a competitive industry with increasing market demand for marine aquaculture and seafood processing, indicating potential for future growth [41]. - The company achieved a processing capacity of 58,000 tons/year for aquatic products and a modern cold storage capacity of 80,000 tons [45]. - The company is focused on sustainable development through technological innovation and industry transformation in both marine and health sectors [44]. - The company aims to leverage existing research technology, talent, and resources to enhance the construction of third-party medical testing laboratories and accelerate the development of in vitro diagnostics and precision medicine [117]. - The company plans to establish a dual business strategy focusing on marine and health industries, enhancing profitability and international competitiveness [118]. - The company will develop a comprehensive marine product supply chain, including breeding, ecological farming, deep processing, and sales, to become a leading enterprise in the national fishery sector [119]. Research and Development - The company has obtained a total of 61 medical device registration certificates and EU/UK access qualifications for its testing reagents [46]. - The company has established a marine technology demonstration base and a health breeding laboratory in collaboration with the Chinese Academy of Sciences [45]. - The company’s health division has developed platforms for immunology, mass spectrometry, and molecular technology, enhancing its product offerings [53]. - The company has established nine subsidiaries and two major R&D centers in China and the USA, focusing on four technology platforms [65]. - The company has seven national R&D platforms and nine provincial R&D platforms, enhancing its innovation capabilities [59]. - The company is actively involved in research and development, with over 70 professional technical personnel in the biomedicine and in-vitro diagnostic fields [70]. - The company is focusing on market expansion and product development, although specific new products were not detailed in the report [160]. Market and Sales - The company’s aquatic products are exported to countries including Japan, South Korea, the United States, and the EU [45]. - The company is actively developing new consumer channels and expanding e-commerce sales to increase product awareness [63]. - The in-vitro diagnostic segment generated ¥332,550,032.09, accounting for 52.84% of total revenue, with a remarkable growth of 175.01% year-over-year [72]. - The revenue from the marine aquaculture segment was ¥103,584,940.12, with a slight increase of 3.52% year-over-year [72]. - The company aims to enhance its online sales channel, targeting a 40% increase in e-commerce revenue by the end of 2023 [167]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years [167]. Financial Management and Governance - The company has established a comprehensive internal control management mechanism, but the implementation of related systems has not been effective [195]. - There are significant internal control deficiencies related to non-operating fund occupation and illegal guarantees, which have not been rectified [196]. - The company is committed to strengthening internal controls and risk management, with a focus on enhancing the approval processes and supervision of fund management systems [198]. - The company has received multiple approvals for self-developed diagnostic reagents and instruments, indicating a strong pipeline for future product offerings [147]. - The company has faced administrative penalties and market entry bans due to violations, impacting both the company and its executives [186]. - The company is facing scrutiny from regulatory bodies due to past false statements and failure to disclose significant litigation [185]. Management and Organizational Changes - The company experienced a management change with the resignation of the financial director on January 20, 2022, and the appointment of a new financial director on April 19, 2022 [159]. - The company appointed a new general manager on April 14, 2022, indicating a strategic shift in leadership [159]. - The company has expanded its management team with the hiring of three new vice presidents on September 28, 2022, to enhance operational efficiency [159]. - The board of directors has approved a new incentive plan aimed at aligning management performance with shareholder interests, with a budget of 10 million yuan [173]. - The company has proposed to increase the agenda for the 2021 annual general meeting, indicating ongoing engagement with shareholders [180]. Risks and Challenges - The company is exposed to exchange rate risks, particularly with the appreciation of the RMB, which could negatively impact processing fees and raw material costs, affecting gross margins [138]. - The company has a significant risk of disease transmission in its aquaculture operations, which could lead to substantial economic losses if not managed properly [140]. - The company is facing challenges such as resource occupation, environmental degradation, and weak infrastructure in the aquaculture sector [105]. - The company has faced cash flow shortages for three consecutive years, prompting a restructuring to address funding issues [131]. - The company faces risks related to the long R&D cycle for in vitro diagnostic reagents, which could impact the recovery of initial investments and future benefits if new products are not successfully developed and registered [132].

Financial Performance - The company's operating revenue for Q1 2023 was ¥135,602,385.62, representing a 22.93% increase compared to ¥110,308,450.56 in the same period last year[8] - The net profit attributable to shareholders for Q1 2023 was ¥11,069,061.27, a significant turnaround from a loss of ¥10,672,833.98 in the previous year, marking a 203.71% improvement[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥565,325.34, an improvement of 95.26% from -¥11,921,114.69 in the previous year[8] - Basic and diluted earnings per share for Q1 2023 were both ¥0.01, a 200.00% increase from -¥0.01 in the previous year[8] - Total operating revenue for Q1 2023 was CNY 135,602,385.62, an increase of 22.9% compared to CNY 110,308,450.56 in the same period last year[22] - Net profit for Q1 2023 was CNY 11,009,690.46, a significant turnaround from a net loss of CNY 10,691,694.53 in Q1 2022[23] - Earnings per share for Q1 2023 was CNY 0.01, compared to a loss per share of CNY 0.01 in the previous year[24] - The total comprehensive income for Q1 2023 was CNY 10,724,816.46, compared to a loss of CNY 10,989,571.13 in the same quarter last year[24] Cash Flow and Liquidity - The net cash flow from operating activities was -¥24,726,935.83, a decline of 305.42% compared to -¥6,099,102.20 in the same period last year[8] - The company's cash and cash equivalents decreased from CNY 129,788,588.18 at the beginning of the year to CNY 100,544,241.35, a decline of approximately 22.5%[18] - The net cash flow from investment activities was -2,343,999.90, compared to -7,163,112.64 in the previous year, indicating a significant reduction in cash outflow[26] - The total cash and cash equivalents at the end of the period were 95,258,658.52, down from 198,344,145.05 year-over-year[26] - The net cash flow from financing activities was -1,056,057.93, compared to -974,812.50 in the previous year, showing an increase in cash outflow[26] - The cash flow impact from exchange rate changes was -866,806.81, compared to -201,468.89 in the previous year, reflecting a larger negative impact from currency fluctuations[26] - The company’s cash and cash equivalents decreased by 28,993,800.47 during the quarter, compared to a decrease of 14,438,496.23 in the previous year[26] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,035,417,463.72, a 1.67% increase from ¥2,001,961,772.53 at the end of the previous year[8] - The equity attributable to shareholders at the end of Q1 2023 was -¥1,157,197,318.74, a slight improvement of 0.92% from -¥1,167,981,506.01 at the end of the previous year[8] - The company's total liabilities increased to CNY 3,178,570,692.32 from CNY 3,155,839,817.59, indicating a rise of 0.7%[20] - Total current liabilities rose from CNY 1,629,116,362.97 to CNY 1,654,322,527.73, an increase of approximately 1.5%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21,857[14] - The top ten shareholders hold a combined 13.22% of the shares, with Hunan Youhe Shenzhou being the largest shareholder[14] - The company has entered into a voting rights entrustment agreement with several shareholders, indicating a unified action relationship among them[15] - The company has not disclosed any participation in margin financing activities by the top ten shareholders[15] Challenges and Management Insights - The company reported non-recurring gains totaling ¥11,634,386.61 for the quarter, including government subsidies and other income[9] - The management highlighted that the increase in net profit was primarily due to the rise in operating revenue, while the decrease in cash flow was attributed to reduced cash outflows from operating activities[12] - The company has faced significant challenges, including a severe deterioration in financial conditions leading to an inability to provide a clear audit opinion on financial data[2] - The company is currently undergoing a pre-restructuring process, with uncertainty regarding the acceptance of the restructuring application by the court[16] Research and Development - Research and development expenses for Q1 2023 were CNY 5,206,606.49, a decrease from CNY 5,689,590.11 in Q1 2022[22] Audit and Reporting - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[27] - The company’s board of directors released the first quarter report on April 29, 2023, providing timely updates to stakeholders[27]